Related references
Note: Only part of the references are listed.PTEN Loss Mediates Clinical Cross-Resistance to CDK4/6 and PI3Kα Inhibitors in Breast Cancer
Carlotta Costa et al.
CANCER DISCOVERY (2020)
Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future
Laura M Spring et al.
LANCET (2020)
CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis
Jennifer J. Gao et al.
LANCET ONCOLOGY (2020)
Mechanisms of Sensitivity and Resistance to CDK4/6 Inhibition
Monica Alvarez-Fernandez et al.
CANCER CELL (2020)
Dual Targeting of CDK4/6 and BCL2 Pathways Augments Tumor Response in Estrogen Receptor-Positive Breast Cancer
James R. Whittle et al.
CLINICAL CANCER RESEARCH (2020)
Blockade of CDK7 Reverses Endocrine Therapy Resistance in Breast Cancer
Yasmin M. Attia et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
The application and prospect of CDK4/6 inhibitors in malignant solid tumors
Qi Du et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
Mammalian cell cycle cyclins
Diego Martinez-Alonso et al.
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY (2020)
Decreased ER dependency after acquired resistance to CDK4/6 inhibitors
Masafumi Iida et al.
BREAST CANCER (2020)
The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor-Positive Metastatic Breast Cancer
Seth A. Wander et al.
CANCER DISCOVERY (2020)
Sequential or Concomitant Inhibition of Cyclin-Dependent Kinase 4/6 Before mTOR Pathway in Hormone-Positive HER2 Negative Breast Cancer: Biological Insights and Clinical Implications
Giulia Occhipinti et al.
FRONTIERS IN GENETICS (2020)
Tumour kinome re-wiring governs resistance to palbociclib in oestrogen receptor positive breast cancers, highlighting new therapeutic modalities
Sunil Pancholi et al.
ONCOGENE (2020)
Combined CDK4/6 and Pan-mTOR Inhibition Is Synergistic Against Intrahepatic Cholangiocarcinoma
Xinhua Song et al.
CLINICAL CANCER RESEARCH (2019)
Overcoming CDK4/6 inhibitor resistance in ER-positive breast cancer
Neil Portman et al.
ENDOCRINE-RELATED CANCER (2019)
Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor-Positive Metastatic Breast Cancer
Nicholas C. Turner et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER plus breast cancer
Luigi Formisano et al.
NATURE COMMUNICATIONS (2019)
MicroRNA-Mediated Suppression of the TGF-β Pathway Confers Transmissible and Reversible CDK4/6 Inhibitor Resistance
Liam Cornell et al.
CELL REPORTS (2019)
Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer
Fabrice Andre et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Cyclin-Dependent Kinase 4/6 Inhibitors in Neoadjuvant Endocrine Therapy of Hormone Receptor-Positive Breast Cancer
Lorenzo Rossi et al.
CLINICAL BREAST CANCER (2019)
Mechanisms of Resistance to CDK4/6 Inhibitors: Potential Implications and Biomarkers for Clinical Practice
Amelia McCartney et al.
FRONTIERS IN ONCOLOGY (2019)
EMERALD: Phase III trial of elacestrant (RAD1901) vs endocrine therapy for previously treated ER plus advanced breast cancer
Aditya Bardia et al.
FUTURE ONCOLOGY (2019)
Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: A review
Kamal Pandey et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies
Utthara Nayar et al.
NATURE GENETICS (2019)
A Phase Ib Dose-Escalation and Expansion Study of the BCL2 Inhibitor Venetoclax Combined with Tamoxifen in ER and BCL2-Positive Metastatic Breast Cancer
Sheau W. Lok et al.
CANCER DISCOVERY (2019)
Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER plus breast cancer models resistant to CDK4/6 inhibitors
Hitisha K. Patel et al.
BREAST CANCER RESEARCH (2019)
Hematological adverse effects in breast cancer patients treated with cyclin-dependent kinase 4 and 6 inhibitors: a systematic review and meta-analysis
Loay Kassem et al.
BREAST CANCER (2018)
4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
F. Cardoso et al.
ANNALS OF ONCOLOGY (2018)
Global analysis of advanced/metastatic breast cancer: Decade report (2005-2015)
Fatima Cardoso et al.
BREAST (2018)
MAPK Reliance via Acquired CDK4/6 Inhibitor Resistance in Cancer
Renee de Leeuw et al.
CLINICAL CANCER RESEARCH (2018)
Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3
Dennis J. Slamon et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
Debu Tripathy et al.
LANCET ONCOLOGY (2018)
Clinical significance of plasma cell-free DNA mutations in PIK3CA, AKT1, and ESR1 gene according to treatment lines in ER-positive breast cancer
Takashi Takeshita et al.
MOLECULAR CANCER (2018)
Combined Inhibition of mTOR and CDK4/6 Is Required for Optimal Blockade of E2F Function and Long-term Growth Inhibition in Estrogen Receptor-positive Breast Cancer
Chrysiis Michaloglou et al.
MOLECULAR CANCER THERAPEUTICS (2018)
The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial
Ben O'Leary et al.
CANCER DISCOVERY (2018)
Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway
Zhiqiang Li et al.
CANCER CELL (2018)
CDK4/6 inhibition stabilizes disease in patients with p16-null non-small cell lung cancer and is synergistic with mTOR inhibition
Priya K. Gopalan et al.
Oncotarget (2018)
Cyclin E1 and Rb modulation as common events at time of resistance to palbociclib in hormone receptor-positive breast cancer
Cristina Guarducci et al.
NPJ BREAST CANCER (2018)
Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer
R. Condorelli et al.
ANNALS OF ONCOLOGY (2018)
Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma
Julien Bollard et al.
GUT (2017)
Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence
C. Yang et al.
ONCOGENE (2017)
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2-Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
George W. Sledge et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
Matthew P. Goetz et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Genomic Aberrations that Activate D-type Cyclins Are Associated with Enhanced Sensitivity to the CDK4 and CDK6 Inhibitor Abemaciclib
Xueqian Gong et al.
CANCER CELL (2017)
Mechanisms of Resistance to CDK4/6 Inhibitors in Breast Cancer and Potential Biomarkers of Response
Cristina Guarducci et al.
BREAST CARE (2017)
Single-Cell Dynamics Determines Response to CDK4/6 Inhibition in Triple-Negative Breast Cancer
Uzma S. Asghar et al.
CLINICAL CANCER RESEARCH (2017)
MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2- Metastatic Breast Cancer
Maura N. Dickler et al.
CLINICAL CANCER RESEARCH (2017)
CDK4 phosphorylation status and a linked gene expression profile predict sensitivity to palbociclib
Eric Raspe et al.
EMBO MOLECULAR MEDICINE (2017)
NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor-Positive Breast Cancer
Cynthia X. Ma et al.
CLINICAL CANCER RESEARCH (2017)
Utilizing Tumor and Plasma Liquid Biopsy in Treatment Decision Making for an Estrogen Receptor-Positive Advanced Breast Cancer Patient
Bing Xu et al.
CUREUS JOURNAL OF MEDICAL SCIENCE (2017)
Kinome-Wide RNA Interference Screen Reveals a Role for PDK1 in Acquired Resistance to CDK4/6 Inhibition in ER-Positive Breast Cancer
Valerie M. Jansen et al.
CANCER RESEARCH (2017)
Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer
Maria Teresa Herrera-Abreu et al.
CANCER RESEARCH (2016)
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
G. N. Hortobagyi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Palbociclib and Letrozole in Advanced Breast Cancer
Richard S. Finn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Targeting the RB-E2F pathway in breast cancer
J. Johnson et al.
ONCOGENE (2016)
A gene expression signature of Retinoblastoma loss-of-function is a predictive biomarker of resistance to palbociclib in breast cancer cell lines and is prognostic in patients with ER positive early breast cancer
Luca Malorni et al.
ONCOTARGET (2016)
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
Richard S. Finn et al.
LANCET ONCOLOGY (2015)
Brk/Protein Tyrosine Kinase 6 Phosphorylates p27KIP1, Regulating the Activity of Cyclin D-Cyclin-Dependent Kinase 4 (Publication with Expression of Concern. See vol. 42, 2022)
Priyank Patel et al.
MOLECULAR AND CELLULAR BIOLOGY (2015)
ESR1 mutations-a mechanism for acquired endocrine resistance in breast cancer
Rinath Jeselsohn et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2015)
Challenges in the management of advanced, ER-positive, HER2-negative breast cancer
Christopher D. Hart et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2015)
The history and future of targeting cyclin-dependent kinases in cancer therapy
Uzma Asghar et al.
NATURE REVIEWS DRUG DISCOVERY (2015)
Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer
Nicholas C. Turner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Targeting Cyclin-Dependent Kinases in Human Cancers: From Small Molecules to Peptide Inhibitors
Marion Peyressatre et al.
CANCERS (2015)
CDK 4/6 Inhibitor Palbociclib (PD0332991) in Rb+ Advanced Breast Cancer: Phase II Activity, Safety, and Predictive Biomarker Assessment
Angela DeMichele et al.
CLINICAL CANCER RESEARCH (2015)
Retinoblastoma tumor suppressor pathway in breast cancer: prognosis, precision medicine, and therapeutic interventions
Agnieszka K. Witkiewicz et al.
BREAST CANCER RESEARCH (2014)
Emergence of Constitutively Active Estrogen Receptor-α Mutations in Pretreated Advanced Estrogen Receptor-Positive Breast Cancer
Rinath Jeselsohn et al.
CLINICAL CANCER RESEARCH (2014)
Aurora-A Mitotic Kinase Induces Endocrine Resistance through Down-Regulation of ERα Expression in Initially ERα plus Breast Cancer Cells
Mateusz Opyrchal et al.
PLOS ONE (2014)
ESR1 ligand-binding domain mutations in hormone-resistant breast cancer
Weiyi Toy et al.
NATURE GENETICS (2013)
Activating ESR1 mutations in hormone-resistant metastatic breast cancer
Dan R. Robinson et al.
NATURE GENETICS (2013)
Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors
Jeffry L. Dean et al.
CELL CYCLE (2012)
Multiple Roles of Cyclin-Dependent Kinase 4/6 Inhibitors in Cancer Therapy
Patrick J. Roberts et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2012)
Cyclin E2 Overexpression Is Associated with Endocrine Resistance but not Insensitivity to CDK2 Inhibition in Human Breast Cancer Cells
C. Elizabeth Caldon et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
CpG island hypermethylation of BRCA1 and loss of pRb as co-occurring events in basal/triple-negative breast cancer
Olafur Andri Stefansson et al.
EPIGENETICS (2011)
Cyclin D as a therapeutic target in cancer
Elizabeth A. Musgrove et al.
NATURE REVIEWS CANCER (2011)
Dissecting the Unique Role of the Retinoblastoma Tumor Suppressor during Cellular Senescence
Agustin Chicas et al.
CANCER CELL (2010)
RB-pathway disruption in breast cancer Differential association with disease subtypes, disease-specific prognosis and therapeutic response
Adam Ertel et al.
CELL CYCLE (2010)
Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure
J. L. Dean et al.
ONCOGENE (2010)
High prevalence of retinoblastoma protein loss in triple-negative breast cancers and its association with a good prognosis in patients treated with adjuvant chemotherapy
D. Trere et al.
ANNALS OF ONCOLOGY (2009)
PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro
Richard S. Finn et al.
BREAST CANCER RESEARCH (2009)
Cellular mechanisms of tumour suppression by the retinoblastoma gene
Deborah L. Burkhart et al.
NATURE REVIEWS CANCER (2008)
Secrets of a double agent: CDK7 in cell-cycle control and transcription
RP Fisher
JOURNAL OF CELL SCIENCE (2005)
Cyclin E in normal and neoplastic cell cycles
HC Hwang et al.
ONCOGENE (2005)
Mammalian cells cycle without the D-type cyclin-elependent kinases Cdk4 and Cdk6
M Malumbres et al.
CELL (2004)
To cycle or not to cycle: A critical decision in cancer
M Malumbres et al.
NATURE REVIEWS CANCER (2001)
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
T Sorlie et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Molecular portraits of human breast tumours
CM Perou et al.
NATURE (2000)
Share Paper
